このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

不完全脊髄損傷(SCI)後の脳制御脊髄刺激歩行療法

2026年9月29日 更新者:Matija Milosevic、University of Miami

不完全脊髄損傷(SCI)後の歩行回復のための脳制御脊髄刺激療法

The purpose of this research is to test the effectiveness of a new therapy, called Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS), for improving walking in people with an incomplete spinal cord injury (SCI).

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (実際)

6

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

    • Florida
      • Miami、Florida、アメリカ、33136
        • University of Miami

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~70年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. At least 18 years old and no older than 70 years old at the time of enrollment.
  2. Traumatic incomplete spinal cord injury (neurological level at or above T10 spinal cord level; Abbreviated Injury Scale (AIS) C or D impairment grade for group 1, 3 and 4 and AIS B, C or D impairment grade for group 2), who are more than 6 months post-injury.
  3. Has detectable motor function in at least 2 muscles per side confirmed by voluntary Electromyography (EMG) or detectable tibialis anterior (TA) muscle motor evoked potentials (MEPs) at the baseline assessment.
  4. Able to commit to intensive training and assessment sessions over a maximum total duration of 12 months (6 months of treatment).
  5. Could effectively walk overground for at least 10 meters with some assistance of a therapist and minimal body-weight support, with functional spasticity (by participant's self-report), functional range-of-motion of lower limb joints, and acceptable bone mass to enable body-weight support, confirmed by Dual-energy X-ray absorptiometry (DXA) scan.

Exclusion Criteria:

  1. Has traumatic brain injury, stroke, multiple sclerosis, or other neuromuscular disorders that could affect neuromotor function and walking.
  2. Has severe spasticity that could prevent stepping and walking function determined by the investigator.
  3. Has major executive dysfunction, dementia, depression, neurocognitive impairments, or other major medical co-morbidities.
  4. Has other contra-indications for transcranial magnetic stimulation (TMS) or Transcutaneous Spinal Cord Stimulation (TSCS).
  5. Has a history of recent seizures or poorly managed autonomic dysreflexia that could be triggered by TMS or TSCS.
  6. Has a history of prior intracranial surgery or known lesions that would limit TMS assessments and Brain-Computer Interface (BCI) recordings.
  7. Individuals with metal implants in their head and other implantable devices in the body that could be affected by TMS or TSCS.
  8. Has peripheral neuropathy (diabetic polyneuropathy, entrapment neuropathy, etc.).
  9. Has urinary tract infection, unhealed fracture, contracture, and pressure sore (Braden Scale).
  10. Has breakdown in skin area that will come into contact with electrodes.
  11. Individuals who require therapy or other care that could interfere with participation in the study.
  12. Individuals on investigational drugs or any other intervention known to have a potential impact on neuromotor function.
  13. Individuals with substance disorders, including alcoholism and drug abuse.
  14. Individuals who are pregnant, breastfeeding, or the desire to become pregnant during the study.
  15. In the opinion of the investigators, the study is not safe or appropriate for the participant.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Brain-Computer Interface (BCI)-Transcutaneous Spinal Cord Stimulation (TSCS)

Participants will receive brain-computer interface (BCI)-triggered transcutaneous spinal cord stimulation (tSCS) combined with activity-based training 3 to 4 times per week. The BCI system detects movement attempts and triggers stimulation delivered through the Neostim 5 spinal cord stimulator. Participants will participate in the therapy for up to 12 months.

Participants will receive brain-computer interface (BCI)-triggered transcutaneous spinal cord stimulation (tSCS) using the Neostim 5 spinal cord stimulator during activity-based training sessions. The BCI system detects movement attempts and triggers delivery of transcutaneous spinal cord stimulation. Intervention sessions will occur 3 to 4 times per week throughout the study intervention period.

他の名前:
  • Neostim 5 Spinal Cord Stimulator

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of related neurological deterioration (LEMS)
時間枠:up to 12 months

Lower Extremity Motor Score (LEMS) to assess lower limb muscle function following the American Spinal Injury Association Impairment Scale (ASIA) guidelines. The LEMS evaluates motor function on a scale of 0 (no motor function) to 5 (full motor function).

up to 12 months
Number of treatment related incidence of adverse events (AEs)
時間枠:up to 12 months

Safety will be reported as the incidence of treatment related AEs as assessed by the study doctor

up to 12 months
Number of subjects that complete the study
時間枠:up to 12 months

Safety will be determined by number of subjects that complete the study, as designed.

up to 12 months
Walking function using 10 meter walk test (10MWT)
時間枠:up to 12 months

This is a test of short-distance walking function. The subject will be asked to walk at a comfortable walking speed (CWS) and maximum walking speed (MWS) on a ten-meter straight walkway. Time is measured in meters per seconds.

up to 12 months
Walking function using 6 minute walk test (6MWT)
時間枠:up to 12 months

The object of the test is to walk as far as possible for 6 minutes. The subject will walk at a normal pace around a marked course for 6 minutes. The subject may stop to rest and begin again at will. The distance covered indicates aerobic fitness. The further a subject walks, the better their cardiovascular condition. Units are measured in meters.

up to 12 months

二次結果の測定

結果測定
メジャーの説明
時間枠
Mobility measured by Timed Up and Go (TUG) Test
時間枠:up to 12 months.

The Timed Up and Go test or TUG test is used to help evaluate mobility. It measures, in seconds, how long it takes subjects to stand up, walk 10 feet, turn around, walk back, and sit down.

up to 12 months.
Balance measured by the Berg Balance Scale (BBS)
時間枠:up to 12 months.

BBS is an assessment to determine balance. The BBS consists of 14 items scored on a 5-point ordinal scale, ranging from 0 to 4 (0 indicates lowest level of function; 4 indicates highest level of function), with a maximum total score of 56.

up to 12 months.
Muscular spasticity measured by the Modified Ashworth Scale (MAS)
時間枠:up to 12 months.

The Modified Ashworth Scale is a 6-point scale. Scores range from 0 to 4, where lower scores represent normal muscle tone and higher scores represent spasticity.

up to 12 months.
Muscular spasticity measured by the Pendulum Test
時間枠:up to 12 months.

The Pendulum Test will be used to measure muscular spasticity. During the pendulum test, the participant will be lying on a therapy mat with the lower leg hanging off the edge of the mat. A member of the study staff will support the participant's extended lower leg and then release the leg allowing it to swing freely. This test will be video recorded and the movement of the knee joint will be measured using software on the computer. Muscular spasticity will be calculated by the number of the Relaxation index (R1 and R2) and compared to norms.

up to 12 months.
Walking assistance measured by the Walking Index for Spinal Cord Injury Scale (WISCI II)
時間枠:up to 12 months

WISCI II is an ordinal scale using a rank ordering along a dimension of impairment, from the level of most severe impairment (0) to least severe impairment (20) based on the use of devices, braces and physical assistance of one or more persons. The order of the levels suggests each successive level is a less impaired level than the former.

up to 12 months
Independence as measured by Spinal Cord Independence Measure (SCIM III)
時間枠:up to 12 months

SCIM III assesses performance in activities of daily living Scores range from 0-100, where a score of 0 defines total dependence and a score of 100 is indicative of complete independence.

up to 12 months
Quality of Life using the International Spinal Cord Injury - Quality of Life (ISCI-QOL)
時間枠:up to 12 months

ISCI-QOL consists of three single items on satisfaction with life as a whole, physical health and psychological health using a 0-10 scale where 0=complete dissatisfaction; 10=complete satisfaction.

up to 12 months
Quality of Life measured by the Reintegration to Normal Living (RNL) questionnaires
時間枠:up to 12 months

RNL is a self-report questionnaire that assesses a person's satisfaction with performance in life activities. The RNL index assesses mobility, self-care, daily activity, recreational activity, and family roles.

The RNL includes 11 declarative statements and a composite score will be calculated. Minimum Score = 0; Maximum Score = 100. Higher scores indicate greater reintegration.

up to 12 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

協力者

捜査官

  • 主任研究者:Matija Milosevic, PhD、University of Miami - MSOM

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年5月7日

一次修了 (推定)

2026年12月31日

研究の完了 (推定)

2026年12月31日

試験登録日

最初に提出

2024年5月6日

QC基準を満たした最初の提出物

2024年5月6日

最初の投稿 (実際)

2024年5月9日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月2日

QC基準を満たした最後の更新が送信されました

2026年9月29日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

その他の研究ID番号

  • 20240091

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

はい

米国で製造され、米国から輸出された製品。

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。